Ascentage Pharma Announces Promising Phase 1 Interim Results in Two Clinical Programs to Be Presented at 2018 ASCO Annual Meeting
ROCKVILLE, Md. and HONG KONG, May 21, 2018 /PRNewswire/ -- Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that interim results from two clinical programs will be presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, June 1-5, 2018.
The poster sessions of APG-1252, a novel dual inhibitor of Bcl-2/Bcl-xL, and APG-1387, a IAP inhibitor, will be held on June 4.
"We are excited to present initial clinical experience with two of our pipeline candidates," commented Dr. Dajun Yang, Chairman and CEO of Ascentage. "These unique small molecules address complex, protein-protein interactions involved in apoptotic pathways in cancer. We look forward to continuing these single agent studies as well as combination trials with immunotherapy treatments."
ASCO abstracts include:
Title: A Phase 1 Study of Novel dual Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced Small Cell Lung Cancer (SCLC) or Other Solid Tumor Session Date and Time:Monday, June 4 at 8:00 a.m. ? 11:30 a.m. CDT Abstract Number: 2594
APG-1252 was designed to reduce the target platelet toxicity seen with dual inhibitors Bcl-2/Bcl-xL, while maintaining strong antitumor activity. Preliminary results showed that APG-1252 was well-tolerated with no hematologic toxicity reported. There was one confirmed partial response in a metastatic small cell lung cancer (SCLC) patient. Dose escalation continues in SCLC and other solid tumors.
Title: A Phase 1 Study of a Novel IAP Inhibitor APG-1387 In Patients With Advanced Solid Tumors Session Date and Time:Monday, June 4 at 8:00 a.m. ? 11:30 a.m. CDT Abstract Number: 2593
APG-1387 was well-tolerated with manageable adverse events. Preliminary responses indicated positive host immune responses, suggesting synergy with immunotherapy agents. Studies are continuing with APG-1387 in combination with immunotherapy agents in patients with advanced solid tumors or hematologic malignancies.
About Ascentage Pharma
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com.
Approval based on NETTER-P trial in which Lutathera demonstrated a consistent safety profile and comparable drug exposure between pediatric (ages 12-17) and adult patientsGastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a rare cancer that...
Jesse Patterson has always been more of a self-treatment type of guy when it comes to dealing with his health. So, when the normally active 73-year-old New Holland resident started getting short of breath and felt his lungs burning when he walked any...
Empowered by employee donations and matched by management contributions, Radians® quarterly Tickets for Charity (TFC) program champions local Memphis and Midsouth charities, offering crucial support for sustaining daily operations and expanding their...
Multi-award-winning Civil Rights Attorney and Child Advocate, Areva Martin, in collaboration with the Special Needs Network (SNN), has revealed the distinguished honorees for the 16th Annual A Pink Pump Affair. This noteworthy charity event is...
Convergent Dental, the power behind the Solea® All-Tissue Dental Laser, proudly announces the rebranding of its annual customer event from the "Solea User Group Meeting" to the "Solea Summit." This update reflects the evolution of the event into the...
The Laniado Hospital in Netanya, Israel, is embarking on a crucial initiative to construct the country's first fully sheltered emergency care building. With the support of the Laniado Development Fund, this endeavor aims to enhance public healthcare...